National Comprehensive Cancer Network

About NCCN

Work Group Meets in Russia to Adapt and Translate NCCN Guidelines® for Lymphomas

National Comprehensive Cancer Network® (NCCN®) Guidelines Panel Members participated in a cooperative meeting for the development of Russian national recommendations on diagnostics and treatment of lymphoproliferative diseases in Moscow on December 20, 2012. This work group was assembled to adapt and translate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Lymphoma for use in Russia. The work group was co-chaired by Dr. Irina Poddubnaya, Corresponding Member of the Russian Academy of Medical Science and head of the Oncology Department of the Russian Medical Academy for Postgraduate Education, and Dr. Valery Savchenko, Academician of the Russian Academy of Medical Science and Director of the Hematology Research Center in Moscow. The panel included 18 Russian physicians specializing in lymphomas; Andrew Zelenetz, MD, PhD, of Memorial Sloan-Kettering Cancer Center in New York, chair of NCCN's Non-Hodgkin's Lymphomas Guidelines Panel, and major contributor to NCCN's programs; and Ephraim Hochberg, MD, of Massachusetts General Hospital in Boston, a member of the NCCN Hodgkin Lymphoma panel. Joan McClure, Senior Vice President of Clinical Information and Publications, of NCCN and Mohammed Jahanzeb, MD, Medical Director of the Sylvester Comprehensive Cancer Center, presented information on NCCN Guidelines ® processes and international collaborations.

Management strategies for 12 lymphoma subtypes were discussed, as were diagnostic criteria for differentiating among lymphoma subtypes. The group also developed recommendations for the management of lymphoma in patients with hepatitis and AIDS-associated lymphoma. The group also considered management of multiple myeloma.

Overall, it was determined that recommendations in the NCCN Guidelines were very similar to those considered the standard of care in Russia and the group reached consensus on NCCN Guidelines adaptations for local use. This is consistent with NCCN experience in Asia, the Middle East, and Latin America. While interpretations or application of the data may differ, physicians around the world use the same clinical trials data to inform their treatment decisions.

If you have any questions regarding the NCCN International program or related activities, please contact Jon Larsen, MPP, Manager, Global Business Development at